First Manhattan CO Biocryst Pharmaceuticals Inc Transaction History

First Manhattan CO

  • $31.9 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$7.94 - $11.84 $7.89 Million - $11.8 Million
-993,832 Reduced 53.18%
874,840 $7.3 Million
Q4 2022

Feb 14, 2023
BUY
$10.5 - $14.2 $667,800 - $903,120
63,600 Added 3.52%
1,868,672 $21.5 Million
Q2 2022

Aug 15, 2022
BUY
$7.89 - $17.88 $14.2 Million - $32.3 Million
1,805,072 New
1,805,072 $19.1 Million

Others Institutions Holding BCRX

# of Institutions
279
Shares Held
172M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email